Trials / Unknown
UnknownNCT04724031
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Hellenic Cooperative Oncology Group · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- —
Summary
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
Detailed description
A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PARP inhibitor | use at any line of treatment in patients with advanced ovarian cancer |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2021-06-30
- Completion
- 2023-09-30
- First posted
- 2021-01-26
- Last updated
- 2023-03-14
Locations
1 site across 1 country: Greece
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04724031. Inclusion in this directory is not an endorsement.